Health & Medicine

STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill

28 sec read29 views0 listens

Structure Therapeutics reported that their daily obesity pill resulted in a 16% weight loss relative to placebo after 44 weeks in Phase 2 trials, positioning them to compete against Eli Lilly and Novo Nordisk in developing oral GLP-1 treatments. This significant result outperforms recent competitors like Lilly's orforglipron, which showed only an 11% weight loss, highlighting the potential for Structure Therapeutics' pill in the obesity treatment market.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Fitness & Wellness13 hours ago29 sec read

Google Health gets better workout logging, improved maps, and Health Connect fixes

Google Health 5.07 introduces enhanced features for workout logging, improved maps for various running conditions, and fixes for Health Connect stability issues affecting Android users. These updates address user feedback and improve navigation and f...

Ali Nemati

Fitness & Wellness13 hours ago25 sec read

First Bilateral Sleep Apnea Implant Performed in Pacific Northwest Outpatient Center

A Portland-based surgical center has performed the first bilateral hypoglossal nerve stimulation implant for sleep apnea in an outpatient setting, marking a significant advancement in regional treatment options. This FDA-approved therapy offers patie...

Ali Nemati

Real Estate & Home1 day ago57 sec read

The top three features that make strata fees worth it, according to buyers

Based on the article, here are the top three features that make strata fees worthwhile for buyers: Resort-style pools and amenities: Fully equipped gyms with high-end equipment Spa facilities like saunas and steam rooms Private resort settings w...

Ali Nemati